Aimmune Gets $145m From Nestlé To Advance Food Allergy Immunotherapies

With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.